Fresenius Medical Care slides as Q1 revenue drops 6% on weak dollar, divestitures
FMS•Fresenius Medical Care shares fell after reporting Q1 2026 results showing a 6% revenue decline, largely driven by a weaker U.S. dollar and recent divestitures. The company also flagged one-time transformation costs that pressured reported profit despite underlying operational progress.
1. What’s moving the stock
Fresenius Medical Care (FMS) is down after releasing first-quarter 2026 results on May 5, 2026 that showed reported revenue falling 6% year over year. The decline was attributed primarily to significant currency headwinds—especially translation from a weaker U.S. dollar—and the impact of recent portfolio divestitures. (marketscreener.com)
2. Profitability vs. headline pressure
While the company highlighted operational progress (including improved profitability and adjusted EPS growth), the market reaction focused on weaker reported top-line trends and profit pressure from transformation-related items. The company said one-time transformation program costs contributed to a 14% decline in reported operating income and a 22% drop in reported net income. (marketscreener.com)
3. What investors will watch next
Investors are likely to focus on whether currency and divestiture impacts persist through mid-2026, and how the transformation program’s one-time costs trend versus expected efficiency benefits. Attention is also on operational execution priorities, including the accelerated U.S. rollout of the 5008X CAREsystems platform that management is emphasizing as part of its ongoing modernization effort. (freseniusmedicalcare.com)
